Key points by Oncology Brothers on Durva+Chemo approval based off AEGEAN trial
H. Jack West, Vice President of Clinical Development at Summit Therapeutics, Inc, shared a post on X by Oncology Brothers adding:
“Will this actually change practice for anyone? If people are already doing neoadjuvant chemo/nivo or peri-operative chemo/pembro f/b pembro post-op, is anyone switching to AEGEAN regimen? If so, what is driving that?”
Luis E. Raez, Medical Director at Memorial Cancer Institute, also commented on this post, adding:
“Great news this approval adds durvalumab as an option for perioperative immunotherapy for early stage NSCLC where we already have pembrolizumab (keynote 671) and nivolumab (checkmate 816 neoadjuvant)”
Quoting Oncology Brothers’s post below:
“Durva + Chemo now approved based off AEGEAN: PeriOp Durva + NeoAdj Chemo -> Cut -> 1year Durva, IIA-IIIB (N2) NSCLC.
- PeriOp IO/Chemo improves pCR 17.2% Vs. 4.3%
- Improved EFS (also seen in CM816). HR: 0.68
- KN671, CM816, and now AEGEAN (awaiting CM77T)”
Source: H. Jack West/Xand Oncology Brothers/X and Luis Raes/X
Drs. Rohit Gosain and Rahul Gosain (aka Oncology Brothers), are medical oncologists/hematologists. Through their social media platforms like X/Twitter, they actively engage with their audience. With their own YouTube channel and podcast, they provide accessible resources for cancer patients and their families. Additionally, their participation in live
conferences ensures that cancer patients receive the best care closer to home, reflecting their commitment to advancing oncology and improving patient outcomes through education and outreach.
